Stefani Sara, Buti Noora, Hart Alice C J, Paul Deena, Rizvi Naghma, Ragoonanan Vashti, Vladescu Camelia, Szydlo Richard, Ademokun Christine, Jansen A J Gerard, Cooper Nichola
Imperial College Healthcare NHS Trust, London, UK.
Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
Br J Haematol. 2024 Jan;204(1):324-328. doi: 10.1111/bjh.19212. Epub 2023 Nov 27.
Multiple studies have reported immune thrombocytopenia (ITP) relapse following SARS-CoV-2 vaccination, however baseline ITP relapse rate and antibody response to vaccination are not known. Patients with ITP who received at least one of the first three SARS-CoV-2 vaccination doses were included in the study. One hundred and twenty-four patients met the inclusion criteria. Relapse rate was 4.2% following a first vaccine dose, 9.1% after a second and 2.9% after a third; baseline relapse rate was 7.6%. Ninety-four per cent of patients who received three vaccine doses developed a clinical antibody response. SARS-CoV-2 vaccination appears to be safe and effective in patients with ITP.
多项研究报告了接种新型冠状病毒2（SARS-CoV-2）疫苗后免疫性血小板减少症（ITP）复发的情况，然而，ITP的基线复发率以及对疫苗接种的抗体反应尚不清楚。本研究纳入了接受至少前三剂SARS-CoV-2疫苗中一剂的ITP患者。124名患者符合纳入标准。首次接种疫苗后的复发率为4.2%，第二次接种后为9.1%，第三次接种后为2.9%；基线复发率为7.6%。接受三剂疫苗的患者中有94%产生了临床抗体反应。SARS-CoV-2疫苗接种在ITP患者中似乎是安全有效的。
